|
|
 |
|
Viewing report
|
|
|
|
Netherlands Pharmaceuticals and Healthcare Report Q1 2009
Business Monitor International, Feb 2009, Pages: 81
Netherlands Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Netherlands's pharmaceuticals and healthcare industry.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Dutch pharmaceutical and healthcare industry.
Competitive intelligence, Dutch pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Dutch market.
The Netherlands Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Our Netherlands Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Dutch pharmaceutical and healthcare industry.
KEY BENEFITS OF REPORT
- Benchmark our Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on the Netherlands to test other views – a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Dutch Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in the Netherlands.
- Exploit The Latest Competitive Dutch Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in the Netherlands.
COVERAGE
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect our forecast analysis, and taken together with our Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
Our 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke our economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
Our 5-Year Macroeconomic Forecasts
Our forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. We profile key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
Customers who bought this item also bought
Netherlands Pharmaceuticals and Healthcare Report Q2 2008
Netherlands Pharmaceuticals and Healthcare Report Q4 2008
Netherlands Pharmaceuticals & Healthcare Report Q1 2008
Netherlands Pharmaceuticals and Healthcare Report Q3 2008
Lithuania Pharmaceuticals & Healthcare Report Q4 2006
The Pharmaceutical Market: Netherlands
Switzerland Pharmaceuticals and Healthcare Report Q1 2009
US Pharmaceuticals and Healthcare Report Q3 2007
Spain Pharmaceuticals and Healthcare Report Q4 2008
Saudi Arabia Pharmaceuticals and Healthcare Report Q1 2008
Bangladesh Pharmaceuticals and Healthcare Report Q4 2008
Hungary Pharmaceuticals & Healthcare Report Q4 2006
|
|
|
|
